Source link : https://newshealth.biz/health-news/fda-reviewing-roflumilast-for-atopic-dermatitis-in-toddlers/
The US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application for topical roflumilast, 0.05%, for the treatment of mild to moderate atopic dermatitis (AD) in children aged 2-5 years, according to a press release from manufacturer Arcutis Biotherapeutics. Topical roflumilast (Zoryve), administered once daily, is a phosphodiesterase-4 inhibitor in a cream […]
Author : News Health
Publish date : 2025-02-27 09:34:17
Copyright for syndicated content belongs to the linked Source.
inHealth